TY - JOUR
T1 - Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
AU - Heinzerling, Keith G.
AU - Shoptaw, Steven
AU - Peck, James A.
AU - Yang, Xiaowei
AU - Liu, Juanmei
AU - Roll, John
AU - Ling, Walter
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Objective: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence. Methods: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples. Results: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use). Conclusions: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
AB - Objective: To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence. Methods: Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (n = 25), gabapentin (n = 26) or placebo (n = 37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples. Results: No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use). Conclusions: While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
KW - Baclofen
KW - Gabapentin
KW - Methamphetamine dependence
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=33749498310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749498310&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2006.03.019
DO - 10.1016/j.drugalcdep.2006.03.019
M3 - Article
C2 - 16740370
AN - SCOPUS:33749498310
VL - 85
SP - 177
EP - 184
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
SN - 0376-8716
IS - 3
ER -